Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and T-ALL Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for NOTCH1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | NOTCH1 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View NOTCH1 Products |
| Gene Delivery | NOTCH1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Ideal for cell-based reporter assays. |
View NOTCH1 Products |
| Benchmark Ab | Anti-NOTCH1 (Sequence of Brontictuzumab) Recombinant positive control. Sequence verified. |
View NOTCH1 Products |
| Validator | NOTCH1 siRNA Set For knockdown verification in target-specificity assays. |
View NOTCH1 Products |
| Related Target A | NOTCH2 Critical for off-target toxicity screening to avoid pan-Notch GI toxicity. |
View NOTCH2 Products |
| Related Target B | DLL4 Key ligand mediating NOTCH1 activation in tumor angiogenesis. |
View DLL4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subfamily off-target screening (NOTCH1 vs NOTCH2/3/4) | Homolog panel proteins strictly verified by mass spectrometry and sequence alignment. |
| Conformation-sensitive antibody screening (NRR domain stabilization) | HEK293-expressed ECD proteins preserving native folding and post-translational modifications. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live NOTCH1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for NOTCH1 therapeutics is intensifying, with major players shifting focus from traditional pan-Notch gamma-secretase inhibitors (GSIs) to selective monoclonal antibodies and bispecifics. As first-generation therapies reach the clinic, the next wave of R&D is targeting conformation-specific epitopes (such as the Negative Regulatory Region, or NRR) to mitigate the severe gastrointestinal toxicities historically associated with pan-NOTCH inhibition.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (mAb) | Oncomed, AbbVie | T-ALL, Solid Tumors | Epitope mapping & binding kinetics (Need high-purity ECD-Fc) |
| Bispecific Antibody | Roche, Regeneron | Angiogenesis, Colorectal Cancer | Heterodimer Validation (Need Cross-reactive Abs and DLL4/JAG1 ligands) |
| Small Molecule (GSI/Selective) | Ayala Pharmaceuticals, BMS | Desmoid Tumors, Adenoid Cystic Carcinoma | Selectivity Assay (Need Mutant vs WT Proteins and stable reporter cell lines) |